LA PROPRIETE INTELLECTUELLE AU COEUR DE LA STRATEGIE DE GENFIT 

Depuis sa création, la société a mis en place une organisation chargée d’arrêter et de préserver les actifs générés dans le cadre de la Propriété Intellectuelle (PI) tout en renforçant son assise stratégique et en contribuant à son développement.

A la charge du département PI, la gestion, l’analyse et la protection de l’ensemble des actifs générés dans le cadre de la recherche interne mais également dans le cadre de programmes de recherche collaboratifs menés avec les partenaires industriels et académiques.

Genfit s’est ainsi constitué un important portefeuille de brevets composé de nouvelles entités chimiques, formules et compositions pharmaceutiques, matériel biologique, outils diagnostiques, et méthodes et outils de recherche.

 

Les publications et communications scientifiques de Genfit

Une sélection des publications et communications scientifiques de Genfit est détaillée ci-dessous.

• Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity
  Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC, Staels B.
  Mol Endocrinol. 2008 Nov; 22(11):2433-47
• Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-{alpha} Control of the Acute-Phase Response
  Roxane M. Mansouri, Eric Baugé, Bart Staels, and Philippe Gervois
  Endocrinology, Jun 2008; 149: 3215 - 3223
• ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in liver
  Pierre-Damien Denechaud, Pascale Bossard, Jean-Marc A. Lobaccaro, Lesley Millatt, Bart Staels, Jean Girard, and Catherine Postic
  Journal of Clinical Investigation, March 2008; 118 (3) 956-964
• Changes in gene expression in skeletal muscle in response to fat overfeeding in lean men
  E. Meugnier - C. Bossu - M. Oliel - S. Jeanne - A. Michaut - M. Sothier - J. Brozek - S. Rome - M. Laville - H. Vidal
  Obesity, 2007, 15 (11), p. 2583
• Safety issues and prospects for future generations of PPAR modulators
  Anne Rubenstrunk, Rémy Hanf, Dean W. Hum, Jean-Charles Fruchart, Bart Staels
  BBA - Molecular and Cell Biology of Lipids, Aug 2007; 1771(8): 1065-81
• PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
  Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G.
  Cell Metab. 2007 Aug;6(2):96-8
• TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone
  Gizard F, Robillard R, Gross B, Barbier O, Révillion F, Peyrat JP, Torpier G, Hum DW, Staels B.
  Mol. Cell. Biol. 2006; 26: 7632-7644
• Protein kinase C pathway promotes Farnesoid X Receptor transcriptional activity
  R.Gineste, A.Sirvent, R. Paumelle, A. Aquilina, S.Helleboid, R.Darteil, DW.Hum, JC. Fruchart, B.Staels
  2006.08.29 Med Chem - FXR – CM
• Early Diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
  R. Shiri-Sverdlov - K. Wouters - P. J. Van Gorp - M. J. Gijbels - B. Noêl - L. Buffat - B,.Staels -N. Maeda - M. van Bilsen - M. H. Hofker
  J Hepatol. 2006-Apr;44(4):732-41
• Sorting out the roles of PPARa in energy metabolism and vascular homeostasis
  Lefebvre P, Chinetti G, Fruchart JC and Staels B
  The Journal of Clinical Investigation, 2006, 116 (3), 571-581
• Effects of Niacin on plasma lipids of wild type and PPARa-KO mice
  R. Hanf , A. Rubenstrunk, F. Contard and JC Fruchart
  EASD 2006
• The Neuroprotective Effect of Atorvastatin in a Murine MCAO Model Is Dependent on PPARalpha
  Sayah-Jeanne S, Bordet R, Laprais M, Poulain P, Coussaert A, Duriez P, Hanf R, Laskey R, Sasiela W, Hum D, Staels B and Fruchart JC
  Stroke. 2006 Feb. 37(2)P432
• Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
  Chinetti-Gbaguidi G, Fruchart JC and Staels B
  Curr Opin Pharmacol, 2005, 5 (2), 177-83 
• Peroxisome Proliferator-Activated Receptor b/d: A novel target for the reduction of atherosclerosis
  Gross BS, Fruchart JC and Staels B
  Drug Discovery Today: Therapeutic Strategies, 2005, 2 (3), 237-243
• Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation
  Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P and Staels B
  Arterioscler Thromb Vasc Biol, 2005, 25 (3), 585-91 
• TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1
  Gizard F, Robillard R, Barbier O, Quatannens B, Faucompre A, Revillion F, Peyrat JP, Staels B and Hum DW
  Mol Cell Biol, 2005, 25 (11), 4335-48 
• Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene
  Gizard F, Robillard R, Gervois P, Faucompre A, Revillion F, Peyrat JP, Hum WD and Staels B
  FEBS Lett, 2005, 579 (25), 5535-41
• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity
  Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B and Kintscher U
  Diabetes, 2005, 54 (12), 3442-52 
• PPARgamma activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes
  Schupp M, Gineste R, Clemenz M, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B and Kintscher U
  3rd International Symposium on PPARs efficacy and safety - Abstract book, 2005
• Farnesoid X receptor represses hepatic lipase gene expression
  Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart JC and Staels B
  J Lipid Res, 2004, 45 (11), 2110-5 
• The farnesoid X receptor induces very low density lipoprotein receptor gene expression
  Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, Hum DW, Fruchart JC and Staels B
  FEBS Lett, 2004, 566 (1-3), 173-7